

THE EXTRAORDINARY SHAREHOLDERS' MEETING OF DIASORIN AUTHORIZES THE CONVERTIBILITY OF THE EQUITY-LINKED BOND AND THE SHARE CAPITAL INCREASE

Saluggia, October 4th, 2021 – The Extraordinary Shareholders' Meeting of DiaSorin S.p.A. (FTSE MIB: DIA) ("**Diasorin**"), held today, approved the proposal on the agenda and, therefore, authorized the convertibility into ordinary shares of DiaSorin of the equity-linked bond named "*€500 million Zero Coupon Equity Linked Bonds due 2028*", issued for an aggregate nominal amount of Euro 500,000,000 on May 5, 2021 and due on May 5, 2028, (the "**Bonds**"). Consequently, the Extraordinary Shareholders' Meeting also approved the share capital increase, payable and in a divisible form, with the exclusion of pre-emption rights pursuant to article 2441, paragraph 5 of the Italian Civil Code, for an aggregate amount of Euro 500,000,000, inclusive of share premium, with the sole purpose to serve the conversion of the Bonds, to be executed in one or more tranches by way of issuance of DiaSorin ordinary shares with regular entitlement and having the same characteristics of the outstanding ordinary shares, thus amending Article 5 of the by-laws.

The minutes of the meeting and the updated version of the by-laws will be made available to the public at the Company's registered office and on the Company's corporate website (www.diasoringroup.com, section "Governance/Information for Shareholders/Shareholders meetings and board/2021") in the manner and within the terms provided for by the applicable legislation.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

DIASORIN

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centres. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com.